SE516554C2 - Uppmätt elektrodos - Google Patents

Uppmätt elektrodos

Info

Publication number: SE516554C2
Authority: SE; Sweden
Prior art keywords: dose; electrode; powder; measured; device element
Prior art date: 2000-08-31

Application number

SE0003082A

Other languages

English (en)

Swedish (sv)

Other versions

SE0003082D0 (sv

SE0003082L (sv

Inventor

Thomas Nilsson

Lars-Gunnar Nilsson

Original Assignee

Microdrug Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-08-31

Filing date

2000-08-31

Publication date

2002-01-29

2000-08-31 Application filed by Microdrug Ag filed Critical Microdrug Ag

2000-08-31 Priority to SE0003082A priority Critical patent/SE516554C2/sv

2000-08-31 Publication of SE0003082D0 publication Critical patent/SE0003082D0/xx

2000-09-18 Priority to US09/664,385 priority patent/US6868853B1/en

2001-07-27 Priority to KR10-2003-7002893A priority patent/KR20030066606A/ko

2001-07-27 Priority to CA002418039A priority patent/CA2418039A1/en

2001-07-27 Priority to PL01360177A priority patent/PL360177A1/pl

2001-07-27 Priority to PCT/SE2001/001683 priority patent/WO2002018000A1/en

2001-07-27 Priority to JP2002522969A priority patent/JP2004516046A/ja

2001-07-27 Priority to RU2003101911/15A priority patent/RU2003101911A/ru

2001-07-27 Priority to BR0113410-8A priority patent/BR0113410A/pt

2001-07-27 Priority to CNA018170943A priority patent/CN1468121A/zh

2001-07-27 Priority to AU2001280352A priority patent/AU2001280352A1/en

2001-07-27 Priority to EP01958731A priority patent/EP1315532A1/en

2002-01-29 Publication of SE0003082L publication Critical patent/SE0003082L/

2002-01-29 Publication of SE516554C2 publication Critical patent/SE516554C2/sv

Links

239000000843 powder Substances 0.000 claims abstract description 63
239000002245 particle Substances 0.000 claims abstract description 51
239000000126 substance Substances 0.000 claims abstract description 19
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
230000000694 effects Effects 0.000 claims abstract description 9
238000009472 formulation Methods 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims abstract description 3
238000000034 method Methods 0.000 claims description 49
239000000463 material Substances 0.000 claims description 30
238000009826 distribution Methods 0.000 claims description 17
230000008569 process Effects 0.000 claims description 16
230000005684 electric field Effects 0.000 claims description 15
238000005259 measurement Methods 0.000 claims description 15
229940112141 dry powder inhaler Drugs 0.000 claims description 14
238000004458 analytical method Methods 0.000 claims description 10
239000004020 conductor Substances 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 9
238000005054 agglomeration Methods 0.000 claims description 8
230000002776 aggregation Effects 0.000 claims description 8
238000004364 calculation method Methods 0.000 claims description 8
239000002904 solvent Substances 0.000 claims description 7
238000004128 high performance liquid chromatography Methods 0.000 claims description 6
238000005516 engineering process Methods 0.000 claims description 5
-1 e.g. Ge Substances 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
238000005457 optimization Methods 0.000 claims description 3
231100000252 nontoxic Toxicity 0.000 claims description 2
230000003000 nontoxic effect Effects 0.000 claims description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
229910052787 antimony Inorganic materials 0.000 claims 2
WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 claims 2
239000004065 semiconductor Substances 0.000 claims 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
229910005542 GaSb Inorganic materials 0.000 claims 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
238000003556 assay Methods 0.000 claims 1
230000015572 biosynthetic process Effects 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
229910002092 carbon dioxide Inorganic materials 0.000 claims 1
239000001569 carbon dioxide Substances 0.000 claims 1
239000012876 carrier material Substances 0.000 claims 1
230000006837 decompression Effects 0.000 claims 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
238000010191 image analysis Methods 0.000 claims 1
238000003703 image analysis method Methods 0.000 claims 1
WPYVAWXEWQSOGY-UHFFFAOYSA-N indium antimonide Chemical compound [Sb]#[In] WPYVAWXEWQSOGY-UHFFFAOYSA-N 0.000 claims 1
230000010355 oscillation Effects 0.000 claims 1
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims 1
235000012239 silicon dioxide Nutrition 0.000 claims 1
239000000377 silicon dioxide Substances 0.000 claims 1
229910001220 stainless steel Inorganic materials 0.000 claims 1
239000010935 stainless steel Substances 0.000 claims 1
XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 claims 1
229910001887 tin oxide Inorganic materials 0.000 claims 1
239000010419 fine particle Substances 0.000 abstract 1
238000012360 testing method Methods 0.000 description 18
238000000151 deposition Methods 0.000 description 8
210000004072 lung Anatomy 0.000 description 7
102000004196 processed proteins & peptides Human genes 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
239000013543 active substance Substances 0.000 description 6
239000011810 insulating material Substances 0.000 description 6
230000001419 dependent effect Effects 0.000 description 5
230000008021 deposition Effects 0.000 description 5
239000003814 drug Substances 0.000 description 5
238000006073 displacement reaction Methods 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
238000012546 transfer Methods 0.000 description 4
238000010586 diagram Methods 0.000 description 3
239000000122 growth hormone Substances 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
239000000758 substrate Substances 0.000 description 3
102000055006 Calcitonin Human genes 0.000 description 2
108060001064 Calcitonin Proteins 0.000 description 2
102000006771 Gonadotropins Human genes 0.000 description 2
108010086677 Gonadotropins Proteins 0.000 description 2
102000018997 Growth Hormone Human genes 0.000 description 2
108010051696 Growth Hormone Proteins 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
102000009151 Luteinizing Hormone Human genes 0.000 description 2
108010073521 Luteinizing Hormone Proteins 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
229960004015 calcitonin Drugs 0.000 description 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000005686 electrostatic field Effects 0.000 description 2
239000002622 gonadotropin Substances 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
229940040129 luteinizing hormone Drugs 0.000 description 2
239000012907 medicinal substance Substances 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
229960002052 salbutamol Drugs 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical class CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
101800001288 Atrial natriuretic factor Proteins 0.000 description 1
102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
108010075254 C-Peptide Proteins 0.000 description 1
102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
102400000739 Corticotropin Human genes 0.000 description 1
101800000414 Corticotropin Proteins 0.000 description 1
102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 1
108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 1
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000010228 Erectile Dysfunction Diseases 0.000 description 1
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000007072 Nerve Growth Factors Human genes 0.000 description 1
239000008896 Opium Substances 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
102000003982 Parathyroid hormone Human genes 0.000 description 1
108090000445 Parathyroid hormone Proteins 0.000 description 1
102000016611 Proteoglycans Human genes 0.000 description 1
108010067787 Proteoglycans Proteins 0.000 description 1
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003579 anti-obesity Effects 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
229960004436 budesonide Drugs 0.000 description 1
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
238000005056 compaction Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000012611 container material Substances 0.000 description 1
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
229960000258 corticotropin Drugs 0.000 description 1
229940041967 corticotropin-releasing hormone Drugs 0.000 description 1
KLVRDXBAMSPYKH-RKYZNNDCSA-N corticotropin-releasing hormone (human) Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)C(C)C)C(C)C)C1=CNC=N1 KLVRDXBAMSPYKH-RKYZNNDCSA-N 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
229960004281 desmopressin Drugs 0.000 description 1
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
238000001514 detection method Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000010291 electrical method Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000003631 expected effect Effects 0.000 description 1
239000004744 fabric Substances 0.000 description 1
229940028334 follicle stimulating hormone Drugs 0.000 description 1
229960002848 formoterol Drugs 0.000 description 1
BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000001434 glomerular Effects 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
102000058004 human PTH Human genes 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
230000006698 induction Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
229960004338 leuprorelin Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000010297 mechanical methods and process Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229960001027 opium Drugs 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000012856 packing Methods 0.000 description 1
239000000199 parathyroid hormone Substances 0.000 description 1
229960001319 parathyroid hormone Drugs 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
229960004017 salmeterol Drugs 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
229960002646 scopolamine Drugs 0.000 description 1
230000011664 signaling Effects 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229940075620 somatostatin analogue Drugs 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229940034208 thyroxine Drugs 0.000 description 1
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
238000004448 titration Methods 0.000 description 1
108091006106 transcriptional activators Proteins 0.000 description 1
108091006107 transcriptional repressors Proteins 0.000 description 1
230000007704 transition Effects 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/02—Inhalators with activated or ionised fluids, e.g. electrohydrodynamic [EHD] or electrostatic devices; Ozone-inhalators with radioactive tagged particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Electrotherapy Devices (AREA)
Battery Electrode And Active Subsutance (AREA)
Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)

SE0003082A 2000-08-31 2000-08-31 Uppmätt elektrodos SE516554C2 (sv)

Priority Applications (12)

Application Number	Priority Date	Filing Date	Title
SE0003082A SE516554C2 (sv)	2000-08-31	2000-08-31	Uppmätt elektrodos
US09/664,385 US6868853B1 (en)	2000-08-31	2000-09-18	Metered electro-dose
EP01958731A EP1315532A1 (en)	2000-08-31	2001-07-27	Metered electro-dose
JP2002522969A JP2004516046A (ja)	2000-08-31	2001-07-27	計量電気投与量
CA002418039A CA2418039A1 (en)	2000-08-31	2001-07-27	Metered electro-dose
PL01360177A PL360177A1 (pl)	2000-08-31	2001-07-27	Odmierzona elektro-dawka
PCT/SE2001/001683 WO2002018000A1 (en)	2000-08-31	2001-07-27	Metered electro-dose
KR10-2003-7002893A KR20030066606A (ko)	2000-08-31	2001-07-27	정량의 전기-투여량
RU2003101911/15A RU2003101911A (ru)	2000-08-31	2001-07-27	Отмеренная электродоза
BR0113410-8A BR0113410A (pt)	2000-08-31	2001-07-27	Dose eletrostática medida
CNA018170943A CN1468121A (zh)	2000-08-31	2001-07-27	经计量的电化剂量
AU2001280352A AU2001280352A1 (en)	2000-08-31	2001-07-27	Metered electro-dose

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE0003082A SE516554C2 (sv)	2000-08-31	2000-08-31	Uppmätt elektrodos

Publications (3)

Publication Number	Publication Date
SE0003082D0 SE0003082D0 (sv)	2000-08-31
SE0003082L SE0003082L (sv)	2002-01-29
SE516554C2 true SE516554C2 (sv)	2002-01-29

Family

ID=20280852

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE0003082A SE516554C2 (sv)	2000-08-31	2000-08-31	Uppmätt elektrodos

Country Status (12)

Country	Link
US (1)	US6868853B1 (pl)
EP (1)	EP1315532A1 (pl)
JP (1)	JP2004516046A (pl)
KR (1)	KR20030066606A (pl)
CN (1)	CN1468121A (pl)
AU (1)	AU2001280352A1 (pl)
BR (1)	BR0113410A (pl)
CA (1)	CA2418039A1 (pl)
PL (1)	PL360177A1 (pl)
RU (1)	RU2003101911A (pl)
SE (1)	SE516554C2 (pl)
WO (1)	WO2002018000A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE524990C2 (sv) *	2002-04-12	2004-11-09	Microdrug Ag	Preparation av terapeutiskt torrt pulver samt förfarande för uppdelning och spridning i luft av medicinskt pulver
SE524957C2 (sv)	2002-04-12	2004-11-02	Microdrug Ag	Förfarande för uppdelning och fördelning i luft av torrt pulvermedikament
AU2002952683A0 (en) *	2002-11-15	2002-11-28	Commonwealth Scientific And Industrial Research Organisation	Apparatus for delivering dry aerosols to the respiratory tract
SE528121C2 (sv) *	2004-03-29	2006-09-05	Mederio Ag	Preparering av torrpulver för på förhand uppmätt DPI
EP1802669B1 (en)	2004-10-21	2011-03-09	Basell Polyolefine GmbH	1-butene polymer and process for the preparation thereof
US7659725B2 (en) *	2006-03-24	2010-02-09	3M Innovative Properties Company	Method for assessing the suitability of metered dose inhaler actuators
EP2077882A2 (en) *	2006-10-25	2009-07-15	Nektar Therapeutics	Powder dispersion apparatus, method of making and using the apparatus, and components that can be used on the apparatus and other devices
US7958683B2 (en) *	2007-10-04	2011-06-14	Hni Corporation	Wall panel system
US9089279B2 (en)	2011-12-29	2015-07-28	General Electric Company	Ion-based breath analysis system
MX392636B (es)	2014-10-31	2025-03-24	Glaxosmithkline Ip Dev Ltd	Formulacion en polvo.
EP3285075A1 (en) *	2016-08-19	2018-02-21	Consejo Superior De Investigaciones Cientificas	Device and method for mapping ferroelectric and/or piezoelectric samples

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5714007A (en) *	1995-06-06	1998-02-03	David Sarnoff Research Center, Inc.	Apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate
SE504458C2 (sv)	1995-06-21	1997-02-17	Lars Gunnar Nilsson	Inhalator för elektrisk dosering av substanser
US5694920A (en)	1996-01-25	1997-12-09	Abrams; Andrew L.	Inhalation device
US6565885B1 (en) *	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US6309623B1 (en) *	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
US6063194A (en) *	1998-06-10	2000-05-16	Delsys Pharmaceutical Corporation	Dry powder deposition apparatus
SE512386C2 (sv)	1998-07-30	2000-03-06	Microdrug Ag	Förfarande och anordning för klassificering av elektrostatiskt laddat pulverformigt material
SE512433C2 (sv)	1998-07-30	2000-03-13	Microdrug Ag	Förfarande för finfördelning och elektrostatisk uppladdning av ett pulver avsett för administrering främst genom inhalation jämte anordning för matning, finfördelning och elektrostatisk uppladdning av ett pulver avsett för administrering främst genom inhalation

2000
- 2000-08-31 SE SE0003082A patent/SE516554C2/sv not_active IP Right Cessation
- 2000-09-18 US US09/664,385 patent/US6868853B1/en not_active Expired - Fee Related
2001
- 2001-07-27 CA CA002418039A patent/CA2418039A1/en not_active Abandoned
- 2001-07-27 CN CNA018170943A patent/CN1468121A/zh active Pending
- 2001-07-27 JP JP2002522969A patent/JP2004516046A/ja active Pending
- 2001-07-27 BR BR0113410-8A patent/BR0113410A/pt not_active Application Discontinuation
- 2001-07-27 RU RU2003101911/15A patent/RU2003101911A/ru not_active Application Discontinuation
- 2001-07-27 EP EP01958731A patent/EP1315532A1/en not_active Withdrawn
- 2001-07-27 WO PCT/SE2001/001683 patent/WO2002018000A1/en not_active Ceased
- 2001-07-27 PL PL01360177A patent/PL360177A1/pl unknown
- 2001-07-27 KR KR10-2003-7002893A patent/KR20030066606A/ko not_active Withdrawn
- 2001-07-27 AU AU2001280352A patent/AU2001280352A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SE0003082D0 (sv)	2000-08-31
EP1315532A1 (en)	2003-06-04
JP2004516046A (ja)	2004-06-03
RU2003101911A (ru)	2004-07-27
CA2418039A1 (en)	2002-03-07
SE0003082L (sv)	2002-01-29
PL360177A1 (pl)	2004-09-06
WO2002018000A1 (en)	2002-03-07
AU2001280352A1 (en)	2002-03-13
CN1468121A (zh)	2004-01-14
US6868853B1 (en)	2005-03-22
KR20030066606A (ko)	2003-08-09
BR0113410A (pt)	2003-07-29

Legal Events

Date	Code	Title	Description
2010-05-05	NUG	Patent has lapsed

Publication	Publication Date	Title
US6881398B2 (en)	2005-04-19	Therapeutic dry powder preparation
JP2004508899A (ja)	2004-03-25	静電式投与型乾燥粉末吸入器の最適化
Prime et al.	1997	Review of dry powder inhalers
AU2001282743B2 (en)	2005-04-07	Electro-powder
US6840239B2 (en)	2005-01-11	De-aggregating and dispersing dry medicament powder into air
AU760126B2 (en)	2003-05-08	Metering, packaging and delivery of pharmaceuticals and drugs
KR101794467B1 (ko)	2017-12-01	건조 분말 약제
AU2001282743A1 (en)	2002-05-16	Electro-powder
SE516554C2 (sv)	2002-01-29	Uppmätt elektrodos
JP2007530671A (ja)	2007-11-01	事前計量されるｄｐｉのための乾燥粉末調合剤
JP2000279518A (ja)	2000-10-10	低吸気吸入投与法における薬剤用量一定供給方法及び装置
JP2003513720A (ja)	2003-04-15	吸入器投薬装置
Ma et al.	2006	A New Technology for Pulmonary Drug Delivery